Apnimed Targets First Oral Sleep Apnea Therapy with FDA NDA
CAMBRIDGE, Mass., July 14, 2026 Apnimed, Inc. has achieved a significant regulatory milestone after the U.S. Food and Drug...
obstructive sleep apnea
Advertisement
Apnimed Appoints Industry Veterans to Drive AD109 Growth
CAMBRIDGE, Mass., July 1, 2026 Apnimed has strengthened its executive leadership team with the appointments of Michael Kelly as...
Novartis and Orionis Expand AI-Powered Molecular Glue Alliance
BOSTON, Massachusetts, USA and GHENT, Belgium, June 10, 2026 Orionis Biosciences and Novartis have announced a major multi-year strategic...
Teva Acquires Emalex to Advance Tourette Syndrome Therapy
TEL AVIV, Israel, June 10, 2026 Teva Pharmaceutical Industries Ltd. has completed its acquisition of Emalex Biosciences, strengthening its...
Eli Lilly and Shaquille O’Neal Raise Awareness of Treatable Sleep Apnea with Zepbound
INDIANAPOLIS, United States, June 10, 2026 Eli Lilly and Company has launched a nationwide awareness campaign featuring NBA legend...
Advertisements
Apnimed Highlights Phase 3 AD109 OSA Data at ATS 2026
CAMBRIDGE, Mass., May 11, 2026 Apnimed announced multiple scientific presentations, including three oral presentations and a late-breaking poster, at...
Nyxoah Begins U.S. Launch of Genio System for Sleep Apnea
MONT-SAINT-GUIBERT, Belgium, Oct. 6, 2025 — Nyxoah SA announced that the first U.S. commercial patients have been implanted with...
Advertisement
